Brian Marckx, CFA
Long/short equity

Cardiac Surgery Rapidly Evolving As Substantial Opportunity For CytoSorbents

Cardiac Surgery A New Major Focus for CytoSorbents

CytoSorbents Corporation (NASDAQ:CTSO) has developed their flagship product, CytoSorb, a sorbent-based cytokine filter, to treat a variety of critical care illnesses through the removal of cytokines and other toxins from the body. The company had an initial focus on sepsis as well as other indications such as respiratory distress syndrome and acute pancreatitis but has recently broadened their scope of potential applications including for use during cardiac surgery.

CytoSorb received CE Mark in March 2011 and launched in Europe towards the end of that year. The company methodically built a small, experienced sales team, began calling on key opinion leaders and built awareness of the device for intervention with critically

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details